This trial is testing a new combination of drugs for patients with advanced or recurrent cervical cancer.
- Cervical Cancer
1 Primary · 4 Secondary · Reporting Duration: 3 years
1 Treatment Group
1 of 1
48 Total Participants · 1 Treatment Group
Primary Treatment: pembrolizumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there any openings to join this medical experiment?
"According to the data on clinicaltrials.gov, this research is currently open for enrolment and was initially posted in December of 2020 with a most recent update taking place in November 2022." - Anonymous Online Contributor
What is the cap on enrollees for this clinical investigation?
"Correct. Clinicaltrials.gov offers evidence that this experiment, initially posted on December 3rd 2020, is currently recruiting subjects. At present, 48 individuals must be enlisted between 2 sites." - Anonymous Online Contributor
Has pembrolizumab been tested in other clinical trials previously?
"Currently, 1114 investigations regarding pembrolizumab are underway with 143 in the third and final stage of a clinical trial. The most significant number of studies for this medication is located in Houston, Texas while there are 42747 total sites operating trials." - Anonymous Online Contributor
Is this a pioneering clinical trial?
"According to the research available, 1114 trials for pembrolizumab have already been conducted in 66 countries and 3058 cities. The inaugural investigation into this medication took place 15 years ago in 2005; it was sponsored by AstraZeneca, included 98 participants, and successfully moved through Phase 1 drug approval. Since then, 313 studies involving this treatment have concluded their work." - Anonymous Online Contributor
To what ailments is pembrolizumab frequently administered?
"Patients with unresectable melanoma, microsatellite instability high ratings, and a heightened risk of recurrence can all be treated with pembrolizumab." - Anonymous Online Contributor
Has the Federal Drug Administration granted authorization for pembrolizumab?
"Due to the presence of clinical evidence indicating safety, pembrolizumab was assigned a score of 2 on our risk assessment scale. No efficacy data is currently available since this trial is in Phase 2." - Anonymous Online Contributor